- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
CD79b Polyclonal Antibody / B29 Rabbit Polyclonal Antibody targets CD79b, a transmembrane glycoprotein encoded by the CD79B gene. Also known as B29 or Ig-beta, CD79b is an essential signaling component of the B-cell antigen receptor (BCR) complex. It associates with CD79a (Ig-alpha) to form a heterodimer that interacts with membrane-bound immunoglobulins, enabling antigen recognition and intracellular signal transmission. The CD79a/CD79b complex is required for efficient assembly and surface expression of the BCR and plays a central role in normal B-cell development, activation, and survival.
CD79b contains an extracellular immunoglobulin-like domain, a transmembrane segment, and a cytoplasmic signaling region. Its cytoplasmic tail includes an immunoreceptor tyrosine-based activation motif (ITAM), which undergoes phosphorylation following antigen engagement. This modification creates docking sites for signaling proteins, including spleen tyrosine kinase (SYK), initiating downstream pathways involving phospholipase C gamma 2 (PLCG2), phosphoinositide 3-kinase (PI3K), and mitogen-activated protein kinases. These signaling cascades regulate calcium mobilization, transcriptional responses, cytoskeletal changes, and processes associated with B-cell proliferation and differentiation.
Beyond antigen-induced activation, CD79b contributes to tonic BCR signaling, which helps maintain the survival of mature B cells. The CD79a/CD79b heterodimer also participates in receptor internalization and antigen processing, linking extracellular antigen recognition with intracellular trafficking and immune responses. Regulation of CD79b phosphorylation, receptor association, and endocytosis influences the strength and duration of BCR signaling. Alterations in these processes can disrupt normal B-cell function and contribute to immune dysregulation.
CD79b is expressed in numerous mature B-cell malignancies, including diffuse large B-cell lymphoma and other B-cell lymphoproliferative disorders. Mutations affecting the CD79B signaling region occur in subsets of activated B-cell-like diffuse large B-cell lymphoma and can promote abnormal BCR signaling. CD79b has also become an important target in antibody-based cancer therapy because of its expression on malignant B cells and its ability to undergo receptor-mediated internalization. CD79b Polyclonal Antibody supports investigations of B-cell receptor signaling, lymphocyte differentiation, immune regulation, and the molecular mechanisms associated with B-cell malignancies.
For an alternative monoclonal antibody targeting this B-cell receptor signaling protein, see our CD79b Antibody IGB/3170R, validated for western blot and immunohistochemistry.
The stated application concentrations are suggested starting amounts. Titration of the CD79b Polyclonal Antibody / B29 Rabbit Polyclonal Antibody may be required due to differences in protocols and secondary/substrate sensitivity.
Human partial recombinant protein (AA 29-229) was used as the immunogen for this CD79b antibody.
After reconstitution, the CD79b antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
B29 antibody, B-cell antigen receptor complex-associated protein beta chain antibody, B-cell receptor-associated protein beta chain antibody, Immunoglobulin beta antibody, Ig-beta antibody, Ig beta antibody, CD79B protein antibody, B-cell antigen receptor CD79b antibody, B-cell receptor signaling protein CD79b antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.